Pasithea Therapeutics CORP (KTTA) 13F Filing Data & Analysis (Q2 2026)

KTTA ranks #7896 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

25 institutions disclose a position in KTTA, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 0.5% of its own portfolio to it.

Cable Car Capital, LP has added to its KTTA position for two straight quarters, increasing it by $901.2K to reach $1.5M today.

Vivo Capital, LLC has trimmed its KTTA position for two straight quarters, cutting it by $2.5M while still holding $239.9K.

KTTA is up 1.8% today, and institutions have been net buyers of $2.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

KTTA reported a net loss of $21.3M over the trailing twelve months.

• Not yet profitable — net loss of $21.3M over the trailing twelve months
• Net income declined year over year, from -$13.5M to -$21.3M
• Operating cash flow was negative, using $15.2M in cash
• Current ratio of 11.35x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range